| abstract |
FIELD: biotechnology.SUBSTANCE: present invention relates to applications α-defensin of a mammal, which is HD5 or HD6, and/or β-defensin of a mammal, which is hBD1, hBD2, truncated hBD2, hBD3 or hBD4, or its variant differing by less than 5 conservative amino acid substitutions. α-defensin and β-defensin is used for treating type 2 diabetes mellitus, metabolic syndrome, systemic nonspecific inflammation, obesity, insulin resistance, impaired glucose tolerance, dysbiotic microbiota in the intestine, as well as for stimulating muscle growth in livestock, increasing diversity of intestinal microbiota genes, increasing the number of phylums of intestinal microbiota, increasing production of short-chain fatty acids of intestinal microbiota, increasing the number of bacteria in the intestines belonging to genus Bacteroidetes, Faecalibacterium, Roseburia, Blautia, Ruminococcus, Coprococcus, Bifidobacterium, Methanobrevibacter, Lactobacillus, Akkermansia, Alloprevotella, Allobaculum and Eubacterium and reducing the number of bacteria in the gut, belonging to genus Bacteroides fragilis, Sutturella wadsworthia, Veillonella parvula, Escherichia coli, Haemophilus parainfluenzae, Fusobacterium nucleatum, Eikenella corrodens and Gemella morbillorum.EFFECT: invention widens the range of equipment.43 cl, 1 tbl, 9 ex, 31 dwg |